OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
11
Results
Show all
Save search
Copy query
Show results for
Unknown
(11)
Publication Date
Release Date
2024
(2)
2022
(2)
2019
(2)
2025
(1)
2023
(1)
2020
(1)
2016
(1)
2010
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Flexible Multi-Beam Light-Sheet Fluorescence Microscope for Live Imaging Without Striping Artifacts.
Not available
S-EPMC6376877
|
biostudies-literature
Cite
Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.
Not available
S-EPMC6697537
|
biostudies-literature
Cite
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".
Not available
S-EPMC6943081
|
biostudies-literature
Cite
MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis.
Not available
S-EPMC10616916
|
biostudies-literature
Cite
Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network.
Not available
S-EPMC8834602
|
biostudies-literature
Cite
Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.
Not available
S-EPMC12380629
|
biostudies-literature
Cite
Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis.
Not available
S-EPMC11338018
|
biostudies-literature
Cite
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study.
Not available
S-EPMC11655126
|
biostudies-literature
Cite
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Not available
S-EPMC5053328
|
biostudies-literature
Cite
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
Not available
S-EPMC9341470
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets